ME02692B - NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA - Google Patents

NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA

Info

Publication number
ME02692B
ME02692B MEP-2017-87A MEP8717A ME02692B ME 02692 B ME02692 B ME 02692B ME P8717 A MEP8717 A ME P8717A ME 02692 B ME02692 B ME 02692B
Authority
ME
Montenegro
Prior art keywords
peptide
seq
nucleic acid
sfnplwlrl
sfnplwlrf
Prior art date
Application number
MEP-2017-87A
Other languages
German (de)
English (en)
French (fr)
Inventor
Toni Weinschenk
Jens Fritsche
Steffen Walter
Peter Lewandrowski
Harpreet Singh
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of ME02692B publication Critical patent/ME02692B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)

Claims (15)

1. Peptid koji ima celokupnu dužinu od između lO i 14 aminokiselina koji sadrži sekvencu izabranu iz grupea) sekvenca koja sadrži ID BR. SEKV 2 i b) varijanta ID BR. SEKV 2 koja indukuje unakrsnu reakciju T ćelija sa navedenim peptidom, naznačeno time što je navedena varijanta izabrana iz grupe sekvenci SFNPLWLRI, SFNPLWLRL, SFNPLWLRF, SFNPLWLRL i SFNPLWLRF za upotrebu u medicini.
2.Peptid za upotrebu u skladu sa patentnim zahtevom l, koji ima sposobnost da se vezuje za molekul humanog glavnog kompleksa gena tkivne podudarnosti (MHC) klase I.
3.Peptid za upotrebu u skladu sa patentnim zahtevom l ili 2, naznačeno time što peptid sadrži nepeptidne veze.
4.Fuzioni protein koji obuhvata peptidnu sekvencu kao deo izabran iz grupe a) sekvence koja se sastoji od ID BR. SEKV 2 i b) varijante ID BR. SEKV 2 izabrane iz grupe sekvenci SFNPLWLRI, SFNPLWLRL, SFNPLWLRF, SFNPLWLRL i SFNPLWLRF, koje konkretno sadrže N-terminalne aminokiseline HLA-DR antigen-asociranog nepromenljivog lanca (Ii).
5.Nukleinska kiselina, koja kodira peptid za upotrebu u skladu sa bilo kojim od patentnih zahteva od l do 4, pod uslovom da peptid nije kompletan humani protein, naznačeno time što je navedena nukleinska kiselina poželjno DNK, cDNK, PNK, RNK ili njihova kombinacija, ili vektor ekspresije koji eksprimira navedenu nukelinsku kiselinu.
6.Nukleinska kiselina ili vektor ekspresije u skladu sa patentnim zahtevom 5 za upotrebu u medicini.
7.Ćelija domaćin, koja sadrži nukleinsku kiselinu ili vektor ekspresije u skladu sa patentnim zahtevom 5, koja je antigen-prezentujuća ćelija. • - 134-
8.Metod za proizvodnju peptida za upotrebu u skladu sa bilo kojim od patentnih zahteva od l do 4, pri čemu metod obuhvata kultiviranje ćelije domaćina u skladu sa patentnim zahtevom 7, kao i izolaciju peptida iz ćelije domaćina ili medijuma za njeno kultiviranje.
9.In vitro metod za proizvodnju aktiviranih citotoksičnih T limfocita (CTL), metod koji se sastoji od dovođenja u kontakt in vitro CTL sa humanim MHC molekulima klase I sa ubačenim antigenom eksprimiranim na površini prikladne antigen-prezentujuće ćelije u toku vremenskog perioda koji je dovoljan da se navedeni CTL aktiviraju na antigen specifičan način, naznačeno time što je navedeni antigen peptid u skladu sa patentnim zahtevom l ili 2.
10. Metod u skladu sa patentnim zahtevom 9, naznačeno time što navedena antigen prezentujuća ćelija sadrži vektor ekspresije koji eksprimira navedeni peptid u skladu sa patentnim zahtevom l ili 2.
11. Aktivirani citotoksični T limfocit (CTL), proizveden metodom u skladu sa patentnim zahtevom 9 ili 10, koji selektivno prepoznaje peptid u skladu sa patentnim zahtevom l ili
12.Citotoksični T limfocit (CTL) u skladu sa patentnim zahtevom ll za upotrebu u lečenju malignog tumora, koji ubija ciljne ćelije kod pacijenta, naznačeno time što navedene ciljne ćelije aberantno prezentuju peptid u skladu sa ID BR. SEKV 2.
13.Peptid u skladu sa patentnim zahtevom l ili 2, nukleinska kiselina ili vektor ekspresije u skladu sa patentnim zahtevom 5, ćelija u skladu sa patentnim zahtevom 7, ili aktivirani citotoksični T limfocit u skladu sa patentnim zahtevom 12 za primenu u lečenju raka, kao što su, na primer, karcinom želuca, gastrointestinalni, kolorektalni, karcinom pankreasa, pluća ili bubrega.
14.Peptid, nukleinska kiselina ili vektor ekspresije, ćelija ili aktivirani citotoksični T limfocit za upotrebu u skladu sa patentnim zahtevom 13, naznačeno time što je navedeni Jek vakcina.
15. Neterapijska upotreba peptida koji ima celokupnu dužinu od između 10 14 aminokiselina, koje obuhvataju sekvencu izabranu iz grupe a) sekvence koja sadrži ID BR. SEKV 2 i b) varijante ID BR. SEKV 2 izabrane iz grupe sekvenci SFNPLWLRI, SFNPLWLRL, ' SFNPLWLRF, SFNPLWLRL i SFNPLWLRF za stvaranje i razvoj antitela koja su specifična protiv kompleksa MHC/peptid koji sadrži navedeni peptid.
MEP-2017-87A 2010-03-19 2011-03-15 NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA ME02692B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31570410P 2010-03-19 2010-03-19
GBGB1004551.6A GB201004551D0 (en) 2010-03-19 2010-03-19 NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP14184348.2A EP2845604B1 (en) 2010-03-19 2011-03-15 Novel immunotherapy against several tumors including gastrointestinal and gastric cancer

Publications (1)

Publication Number Publication Date
ME02692B true ME02692B (me) 2017-10-20

Family

ID=42227949

Family Applications (3)

Application Number Title Priority Date Filing Date
MEP-2019-287A ME03569B (me) 2010-03-19 2011-03-15 Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni karcinom i karcinom želuca
MEP-2017-87A ME02692B (me) 2010-03-19 2011-03-15 NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA
MEP-2015-122A ME02229B (me) 2010-03-19 2011-03-15 NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2019-287A ME03569B (me) 2010-03-19 2011-03-15 Nova imunoterapija protiv nekoliko tumora uključujući gastrointestinalni karcinom i karcinom želuca

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2015-122A ME02229B (me) 2010-03-19 2011-03-15 NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA

Country Status (30)

Country Link
US (25) US10064913B2 (me)
EP (9) EP2845604B1 (me)
JP (10) JP5891181B2 (me)
KR (13) KR20190033577A (me)
CN (8) CN108456242A (me)
AU (1) AU2011229199B2 (me)
BR (1) BR112012023692B1 (me)
CA (5) CA2789857C (me)
CY (5) CY1119366T1 (me)
DK (6) DK3329933T3 (me)
EA (8) EA037019B1 (me)
ES (8) ES2819861T3 (me)
GB (1) GB201004551D0 (me)
HK (1) HK1226297A1 (me)
HR (6) HRP20150867T1 (me)
HU (6) HUE050376T2 (me)
LT (5) LT2923708T (me)
ME (3) ME03569B (me)
MX (7) MX382164B (me)
MY (2) MY178651A (me)
NZ (7) NZ708205A (me)
PH (4) PH12021551360A1 (me)
PL (6) PL3195873T3 (me)
PT (6) PT3329933T (me)
RS (6) RS60993B1 (me)
SG (4) SG183880A1 (me)
SI (6) SI3363456T1 (me)
TW (9) TWI768461B (me)
UA (3) UA111711C2 (me)
WO (1) WO2011113819A2 (me)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7604662B2 (en) 2007-07-13 2009-10-20 Boston Scientific Scimed, Inc. Endoprostheses containing boride intermetallic phases
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
EP2400035A1 (en) * 2010-06-28 2011-12-28 Technische Universität München Methods and compositions for diagnosing gastrointestinal stromal tumors
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
CN104066746B (zh) * 2011-10-28 2017-12-05 肿瘤疗法科学股份有限公司 Topk肽及包含它们的疫苗
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
ES2973957T3 (es) * 2012-03-19 2024-06-25 Stemline Therapeutics Inc Métodos para tratar y monitorizar el estado de un cáncer
SMT202100545T1 (it) 2012-05-16 2021-11-12 Stemline Therapeutics Inc Vaccini contro il cancro mirati alle cellule staminali cancerose
JP6255593B2 (ja) 2012-07-10 2018-01-10 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のＣＤＣＡ１エピトープペプチドおよびこれを含有するワクチン
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
JP6212249B2 (ja) * 2012-08-08 2017-10-11 学校法人 京都産業大学 カルシウムポンプ制御物質のスクリーニング方法、並びに、メラニン色素合成阻害物質のスクリーニング方法
WO2014035695A1 (en) 2012-08-30 2014-03-06 The Board Of Trustees Of The Leland Stanford Junior University Anti-tumor t cell immunity induced by high dose radiation
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
SI3456339T1 (sl) * 2013-08-05 2022-01-31 Immatics Biotechnologies Gmbh Nova imunoterapija proti več tumorjem, kot je pljučni rak, vključno z nedrobnoceličnim pljučnim rakom
EP2876442A1 (en) * 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
MX2016010998A (es) 2014-02-27 2017-03-31 Lycera Corp Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
WO2015164826A2 (en) * 2014-04-24 2015-10-29 Rhode Island Hospital ASPARTATE-β-HYDROXYLASE INDUCES EPITOPE-SPECIFIC T CELL RESPONSES IN TUMORS
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
KR101644599B1 (ko) 2014-10-14 2016-08-16 연세대학교 산학협력단 미토콘드리아 단백질 uqcrb 관련 질환 유전자발현 세포 구축 및 이를 활용한 uqcrb 기능조절 활성평가계 구축
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
TWI755157B (zh) 2015-03-17 2022-02-11 德商英麥提克生物技術股份有限公司 用於抗胰臟癌與其他癌症的免疫治療的新穎胜肽及胜肽的組合
EP4140492A1 (en) 2015-04-21 2023-03-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
HK1253734A1 (zh) 2015-06-11 2019-06-28 The Regents Of The University Of Michigan 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物
JP2018518956A (ja) * 2015-06-19 2018-07-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 免疫療法で使用するための新規ペプチドおよびペプチド組み合わせおよび膵臓がんおよびその他のがんに対して使用するためにスキャフォールドを作製する方法
GB201510771D0 (en) * 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
HRP20202019T1 (hr) 2015-07-01 2021-04-30 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US20170136108A1 (en) * 2015-08-28 2017-05-18 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TWI796642B (zh) 2015-08-28 2023-03-21 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
KR102601499B1 (ko) * 2015-11-06 2023-11-13 연세대학교 산학협력단 miRNA 발현 수준으로부터 UQCRB 관련 질병을 진단하는 방법
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604458D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
SG11201808629UA (en) * 2016-04-21 2018-11-29 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
SG10202006117QA (en) 2016-04-21 2020-08-28 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
AU2017299162B2 (en) * 2016-07-20 2024-09-26 BioNTech SE Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
DE102016115246C5 (de) * 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
KR102381854B1 (ko) * 2016-08-17 2022-04-04 이매틱스 바이오테크놀로지스 게엠베하 T 세포 수용체 및 이를 사용하는 면역 요법
ZA201900664B (en) 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
CN109923121B (zh) 2016-11-22 2022-12-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
CN110167956B (zh) * 2016-11-30 2023-04-07 深圳华大生命科学研究院 多肽及其应用
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
TW201841934A (zh) * 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
AU2018251839B2 (en) * 2017-04-10 2022-06-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
DE102017125888A1 (de) * 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
FI3707159T3 (fi) 2017-11-06 2023-04-18 Immatics Biotechnologies Gmbh Uusia muokattuja t-solureseptoreita ja niitä käyttävä immuuniterapia
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響トランスデューサドライバ及びコントローラ
CA3101310A1 (en) 2018-03-12 2019-09-19 The Children's Hospital Of Philadelphia Methods and compositions for use of tumor self-antigens in adoptive immunotherapy
WO2019243312A1 (en) 2018-06-19 2019-12-26 Dsm Ip Assets B.V. Lipolytic enzyme variants
US20210380661A1 (en) * 2018-10-16 2021-12-09 Texas Tech University System Method to Express, Purify, and Biotinylate Eukaryotic Cell-Derived Major Histocompatibility Complexes
PH12021552979A1 (en) 2019-05-27 2023-10-09 Immatics Us Inc Viral vectors and their use in adoptive cellular therapy
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
CN114303060A (zh) 2019-06-06 2022-04-08 伊玛提克斯生物技术有限公司 使用序列相似肽进行反向选择分选
KR102397922B1 (ko) * 2020-02-19 2022-05-13 서울대학교 산학협력단 신규한 종양-관련 항원 단백질 olfm4 및 이의 용도
WO2021252517A1 (en) * 2020-06-09 2021-12-16 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
EP4206334A4 (en) 2020-08-28 2025-01-01 Industry Academic Cooperation Foundation Keimyung University Micro rna biomarker for predicting drug response to antidiabetics and use thereof
US20240024438A1 (en) * 2020-11-19 2024-01-25 Board Of Regents, The University Of Texas System Methods and compositions comprising mhc class peptides
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
WO2022147029A2 (en) 2020-12-31 2022-07-07 Immatics US, Inc. Cd8 polypeptides, compositions, and methods of using thereof
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
CN114732898B (zh) * 2022-04-01 2023-05-09 中国人民解放军军事科学院军事医学研究院 一种CpG佐剂与抗原定点共价结合方法
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
AU2023262596A1 (en) 2022-04-28 2024-12-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2024072954A1 (en) * 2022-09-29 2024-04-04 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Cold atmopsheric plasma treated pan-cancer epitope peptide within the collagen type vi a-3 (col6a3) protein as cancer vaccine
WO2024077071A2 (en) * 2022-10-05 2024-04-11 The Johns Hopkins University Nanoparticles for delivery of immunoregulatory materials to t cells
JP2026505364A (ja) * 2023-02-08 2026-02-13 ナビジェン， インコーポレイテッド Ｔｎｆ－アルファ結合剤およびそれを使用する方法
CN116102468B (zh) * 2023-02-22 2024-07-09 中国科学技术大学 靶向人脂质运载蛋白2的先导化合物或其药学上可接受的盐及其制备方法与应用
WO2024225764A1 (ko) * 2023-04-26 2024-10-31 한국과학기술원 섬유아세포 활성화 단백질의 면역우세 에피토프 펩타이드 및 이의 용도
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US8299321B2 (en) 1998-06-16 2012-10-30 Monsanto Technology Llc Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
EP1115847A1 (en) * 1998-09-25 2001-07-18 Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2001041787A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
JP4310104B2 (ja) 2002-09-28 2009-08-05 英俊 猪子 マイクロサテライト遺伝多型マーカを用いる遺伝子のマッピング方法
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20070067865A1 (en) 2000-09-05 2007-03-22 Kovalic David K Annotated plant genes
EP1317275A1 (de) * 2000-09-06 2003-06-11 Müller, Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
AU2001294943A1 (en) 2000-10-02 2002-04-15 Bayer Corporation Nucleic acid sequences differentially expressed in cancer tissue
US6673549B1 (en) * 2000-10-12 2004-01-06 Incyte Corporation Genes expressed in C3A liver cell cultures treated with steroids
USH2191H1 (en) 2000-10-24 2007-06-05 Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
WO2002036614A2 (en) * 2000-11-01 2002-05-10 Insight Biotechnology Limited Peptides for use in the treatment of alzheimer's disease
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002078524A2 (en) * 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2002078516A2 (en) * 2001-03-30 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
WO2005024017A1 (en) 2002-03-15 2005-03-17 Monsanto Technology Llc Nucleic acid molecules associated with oil in plants
DE10225139A1 (de) * 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
AU2002368151A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Matrix metalloproteinase inhibitors and methods for identification of lead compounds
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2005049806A2 (en) * 2003-03-14 2005-06-02 Nuvelo, Inc. Novel nucleic acids and polypeptides
US20070037204A1 (en) * 2003-08-08 2007-02-15 Hiroyuki ABURANTAI Gene overexpressed in cancer
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20070054278A1 (en) 2003-11-18 2007-03-08 Applera Corporation Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof
CA2554440A1 (en) * 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US20070039069A1 (en) 2004-03-22 2007-02-15 Rogers James A Nucleic acid molecules associated with oil in plants
TW200600785A (en) 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
AT501014A1 (de) * 2004-08-19 2006-05-15 Kury & Zeillinger Oeg Verfahren und kit zur diagnose einer krebserkrankung, verfahren zum feststellen des ansprechens eines patienten auf die behandlung einer krebserkrankung, therapeutikum zur prophylaxe oder behandlung einer krebserkrankung
WO2007005635A2 (en) 2005-07-01 2007-01-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mitotic spindle protein aspm as a diagnostic marker for neoplasia and uses therefor
EP1760089B1 (en) * 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
ATE461215T1 (de) * 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
GB0521958D0 (en) 2005-10-27 2005-12-07 Ares Trading Sa vWFA, collagen and kunitz domain containing protein
DE102005052384B4 (de) * 2005-10-31 2009-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens
US20080058272A1 (en) * 2006-08-29 2008-03-06 Juergen Becker Nonamer Peptides for Cancer Treatment
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
KR101351195B1 (ko) * 2007-07-27 2014-01-14 이매틱스 바이오테크놀로지스 게엠베하 면역 치료를 위한 새로운 면역원성 에피톱
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
WO2009075883A2 (en) * 2007-12-12 2009-06-18 University Of Georgia Research Foundation, Inc. Glycoprotein cancer biomarker
UA104572C2 (ru) * 2008-04-24 2014-02-25 Имматикс Байотекнолоджиз Гмбх Новые композиции опухолеассоциированных пептидов, которые связываются с молекулами i или ii класса лейкоцитарного антигена человека (hla) для разработки вакцин
KR101184869B1 (ko) * 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
SI2113253T1 (sl) 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
US8133686B2 (en) * 2008-05-15 2012-03-13 Van Andel Research Institute IL-8 as a biomarker for sunitinib resistance
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
PL2172211T3 (pl) 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201015765D0 (en) * 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer

Also Published As

Publication number Publication date
US11883462B2 (en) 2024-01-30
US9993523B2 (en) 2018-06-12
US11850274B2 (en) 2023-12-26
SI3363456T1 (sl) 2021-02-26
US11077171B2 (en) 2021-08-03
JP2020191875A (ja) 2020-12-03
HRP20201467T1 (hr) 2020-12-11
CA2789857C (en) 2017-03-21
CA2789857A1 (en) 2011-09-22
PH12016500949B1 (en) 2017-02-13
KR102324499B1 (ko) 2021-11-09
TW202102534A (zh) 2021-01-16
KR20210019139A (ko) 2021-02-19
SG10201710446PA (en) 2018-01-30
DK3195873T3 (da) 2019-10-21
KR20210019603A (ko) 2021-02-22
US20130045191A1 (en) 2013-02-21
EA202091242A2 (ru) 2021-01-29
EP3753570B1 (en) 2024-10-02
EP2547354A2 (en) 2013-01-23
HK1255544A1 (en) 2019-08-23
US20170312336A1 (en) 2017-11-02
SI2845604T1 (sl) 2017-06-30
EA201792409A3 (ru) 2018-07-31
CA2986969C (en) 2020-04-28
HUE045757T2 (hu) 2020-01-28
US20170304399A1 (en) 2017-10-26
KR102388577B1 (ko) 2022-04-19
ME02229B (me) 2016-02-20
NZ737956A (en) 2020-11-27
CA3076642A1 (en) 2011-09-22
CN108456242A (zh) 2018-08-28
KR102324498B1 (ko) 2021-11-09
TW202102536A (zh) 2021-01-16
UA111711C2 (uk) 2016-06-10
PH12019502194A1 (en) 2020-06-15
CA2986969A1 (en) 2011-09-22
HUE033682T2 (en) 2017-12-28
EP2845604A2 (en) 2015-03-11
EP3363456A1 (en) 2018-08-22
KR20180014848A (ko) 2018-02-09
KR20200108934A (ko) 2020-09-21
US11975042B2 (en) 2024-05-07
US20250049886A1 (en) 2025-02-13
CA3076642C (en) 2023-08-29
KR20220025133A (ko) 2022-03-03
NZ627877A (en) 2015-08-28
EP3738606B1 (en) 2024-10-30
US20190290727A1 (en) 2019-09-26
US20220016207A1 (en) 2022-01-20
US11969455B2 (en) 2024-04-30
BR112012023692B1 (pt) 2020-06-09
HUE050376T2 (hu) 2020-11-30
ES2829375T3 (es) 2021-05-31
AU2011229199A1 (en) 2012-08-16
KR102388761B1 (ko) 2022-04-20
TW202026308A (zh) 2020-07-16
CN112409452A (zh) 2021-02-26
CN112430255A (zh) 2021-03-02
NZ795528A (en) 2024-07-05
KR20200108935A (ko) 2020-09-21
UA126787C2 (uk) 2023-02-08
US12064465B2 (en) 2024-08-20
KR20190033577A (ko) 2019-03-29
EA202091233A3 (ru) 2020-12-30
EP2845604B1 (en) 2017-03-08
SI3195873T1 (sl) 2019-11-29
RS56070B1 (sr) 2017-10-31
CN112409453A (zh) 2021-02-26
US20200330552A1 (en) 2020-10-22
EA202091233A2 (ru) 2020-09-30
NZ601438A (en) 2014-12-24
TW202102535A (zh) 2021-01-16
EP3058947A2 (en) 2016-08-24
MX355074B (es) 2018-04-04
KR20160106192A (ko) 2016-09-09
KR102324500B1 (ko) 2021-11-09
EP2845604A3 (en) 2015-05-20
SG10201502093QA (en) 2015-05-28
NZ769435A (en) 2023-02-24
US20220016209A1 (en) 2022-01-20
PT2547354E (pt) 2015-09-16
EP3329933A1 (en) 2018-06-06
MY197710A (en) 2023-07-09
PL2845604T3 (pl) 2017-09-29
EA201201306A1 (ru) 2013-02-28
EA024497B1 (ru) 2016-09-30
KR102329791B1 (ko) 2021-11-22
EP3738606A1 (en) 2020-11-18
US20200297801A1 (en) 2020-09-24
CN112409451B (zh) 2024-10-01
DK3329933T3 (da) 2020-09-21
JP2022141743A (ja) 2022-09-29
LT3329933T (lt) 2020-09-25
US20180000896A1 (en) 2018-01-04
US20210275634A1 (en) 2021-09-09
CN112409451A (zh) 2021-02-26
EA202091251A2 (ru) 2020-09-30
KR101656913B1 (ko) 2016-09-13
KR20200109392A (ko) 2020-09-22
US20190321442A1 (en) 2019-10-24
US9717774B2 (en) 2017-08-01
US20180125929A1 (en) 2018-05-10
DK3363456T3 (da) 2020-11-09
ES2992110T3 (es) 2024-12-09
JP2018057393A (ja) 2018-04-12
MX2020011675A (es) 2020-12-03
JP5891181B2 (ja) 2016-03-22
RS54182B1 (sr) 2015-12-31
US10933118B2 (en) 2021-03-02
EA202091241A2 (ru) 2021-01-29
US20220265764A1 (en) 2022-08-25
LT2923708T (lt) 2017-10-10
PL3329933T3 (pl) 2020-11-30
TW201200594A (en) 2012-01-01
LT3195873T (lt) 2019-11-11
BR112012023692A2 (pt) 2017-07-18
MX2020011672A (es) 2020-12-03
PT3329933T (pt) 2020-09-22
US10357540B2 (en) 2019-07-23
TWI715332B (zh) 2021-01-01
DK2547354T3 (da) 2015-07-20
JP2021080263A (ja) 2021-05-27
KR20200109390A (ko) 2020-09-22
PT2923708T (pt) 2017-10-06
RS59554B1 (sr) 2019-12-31
TWI486445B (zh) 2015-06-01
US20210260160A1 (en) 2021-08-26
EA201690511A1 (ru) 2016-11-30
TW201825514A (zh) 2018-07-16
CN102905721A (zh) 2013-01-30
TWI659967B (zh) 2019-05-21
CA3206214A1 (en) 2011-09-22
MX382164B (es) 2025-03-13
AU2011229199B2 (en) 2015-01-22
EA202091250A2 (ru) 2020-09-30
SI2923708T1 (sl) 2017-10-30
PT2845604T (pt) 2017-06-01
PH12021551360A1 (en) 2022-11-28
CY1122235T1 (el) 2020-11-25
HRP20150867T1 (hr) 2015-09-25
HRP20201770T1 (hr) 2021-03-19
US10905741B2 (en) 2021-02-02
US9101585B2 (en) 2015-08-11
DK2845604T3 (da) 2017-05-01
MX2020011674A (es) 2020-12-03
US9895415B2 (en) 2018-02-20
EP3195873A1 (en) 2017-07-26
EP2923708A1 (en) 2015-09-30
US10898546B2 (en) 2021-01-26
JP7107586B2 (ja) 2022-07-27
JP2020191874A (ja) 2020-12-03
TWI681967B (zh) 2020-01-11
HRP20170718T1 (hr) 2017-07-14
US11957730B2 (en) 2024-04-16
KR20130016304A (ko) 2013-02-14
JP7007504B2 (ja) 2022-02-10
WO2011113819A3 (en) 2011-11-10
PH12012501821A1 (en) 2017-08-04
KR20200109389A (ko) 2020-09-22
US20210330743A1 (en) 2021-10-28
US20210162004A1 (en) 2021-06-03
TWI766361B (zh) 2022-06-01
LT3363456T (lt) 2021-01-11
WO2011113819A2 (en) 2011-09-22
CY1123762T1 (el) 2022-03-24
HRP20171504T1 (hr) 2017-11-17
EA202091242A3 (ru) 2021-04-30
ES2544529T3 (es) 2015-09-01
NZ731580A (en) 2020-11-27
US20220040259A1 (en) 2022-02-10
CN102905721B (zh) 2015-09-23
GB201004551D0 (en) 2010-05-05
JP2017140027A (ja) 2017-08-17
JP2017006136A (ja) 2017-01-12
US20110229504A1 (en) 2011-09-22
JP6238258B2 (ja) 2017-11-29
KR20230141886A (ko) 2023-10-10
US20210346465A1 (en) 2021-11-11
CY1119366T1 (el) 2018-02-14
HUE027036T2 (en) 2016-08-29
TWI766362B (zh) 2022-06-01
PH12016500949A1 (en) 2017-02-13
CY1119739T1 (el) 2018-06-27
NZ711296A (en) 2017-03-31
MY178651A (en) 2020-10-20
CA2936642C (en) 2019-03-05
HK1210586A1 (en) 2016-04-29
ES2642562T3 (es) 2017-11-16
JP2024116331A (ja) 2024-08-27
PT3195873T (pt) 2019-10-31
EP3753570A1 (en) 2020-12-23
US11648292B2 (en) 2023-05-16
EA201792409A2 (ru) 2018-03-30
JP6722644B2 (ja) 2020-07-15
HK1208174A1 (en) 2016-02-26
PL2547354T3 (pl) 2015-12-31
RS56612B1 (sr) 2018-02-28
MX2012010813A (es) 2012-11-12
US11273200B2 (en) 2022-03-15
EA202091241A3 (ru) 2021-04-30
JP2013521789A (ja) 2013-06-13
EP3329933B1 (en) 2020-06-24
EA039357B1 (ru) 2022-01-18
EP3058947A3 (en) 2016-11-30
ES2753206T3 (es) 2020-04-07
US11839643B2 (en) 2023-12-12
US20210268063A1 (en) 2021-09-02
KR101826460B1 (ko) 2018-02-06
MX2020011673A (es) 2020-12-03
PL2923708T3 (pl) 2018-03-30
UA122047C2 (uk) 2020-09-10
NZ708205A (en) 2015-09-25
SG183880A1 (en) 2012-10-30
HK1226297A1 (en) 2017-09-29
CA2936642A1 (en) 2011-09-22
EP2923708B1 (en) 2017-07-12
TW201529849A (zh) 2015-08-01
TWI621709B (zh) 2018-04-21
JP6103608B2 (ja) 2017-03-29
SI3329933T1 (sl) 2021-01-29
CN105001339B (zh) 2020-10-16
US20200155645A1 (en) 2020-05-21
RS60765B1 (sr) 2020-10-30
TW201805301A (zh) 2018-02-16
SG10201606771SA (en) 2016-10-28
CY1123447T1 (el) 2021-12-31
EP2547354B1 (en) 2015-06-03
ES2819861T3 (es) 2021-04-19
DK2923708T3 (en) 2017-10-16
HK1180610A1 (en) 2013-10-25
HUE032402T2 (en) 2017-09-28
US20150147347A1 (en) 2015-05-28
SI2547354T1 (sl) 2015-09-30
KR102361467B1 (ko) 2022-02-14
JP2016034950A (ja) 2016-03-17
CN105001339A (zh) 2015-10-28
TW202300509A (zh) 2023-01-01
ES2993310T3 (en) 2024-12-27
PL3195873T3 (pl) 2020-03-31
US10064913B2 (en) 2018-09-04
ES2626798T3 (es) 2017-07-26
JP6535040B2 (ja) 2019-06-26
US11298404B2 (en) 2022-04-12
US10420816B1 (en) 2019-09-24
EP3195873B1 (en) 2019-07-24
EA037019B1 (ru) 2021-01-27
EA202091250A3 (ru) 2020-12-30
US10478471B2 (en) 2019-11-19
HUE051478T2 (hu) 2021-03-01
JP7034505B2 (ja) 2022-03-14
US20220008506A1 (en) 2022-01-13
RS60993B1 (sr) 2020-11-30
PT3363456T (pt) 2020-11-10
CN112457390A (zh) 2021-03-09
EP3363456B1 (en) 2020-08-05
PL3363456T3 (pl) 2021-05-04
ME03569B (me) 2020-07-20
EA202091251A3 (ru) 2020-12-30
US20210346466A1 (en) 2021-11-11
NZ727841A (en) 2019-11-29
TWI768461B (zh) 2022-06-21
LT2845604T (lt) 2017-04-25
HRP20191859T1 (hr) 2019-12-27
NZ769427A (en) 2023-02-24

Similar Documents

Publication Publication Date Title
ME02692B (me) NOVA IMUNOTERAPIJA PROTIV NEKOLIKO TUMORA UKLJUČUJUĆI GASTROINTESTINALNI KARCINOM l KARCINOM ŽELUCA
HRP20201228T1 (hr) Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga
AR121383A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
HRP20202019T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
JP2013521789A5 (me)
HRP20150108T1 (hr) Peptidna cjepiva za rak koji eksprimira tumoru pridružene antigene
JP2020198875A5 (me)
JP2010534463A5 (me)
HRP20210076T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma ezofagusa i drugih karcinoma
HRP20201281T1 (hr) Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv epitelnog karcinoma jajnika i drugih karcinoma
JP2009506762A5 (me)
HRP20210709T1 (hr) Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma
JP2018509135A5 (me)
JP2019502360A5 (me)
DK1759013T3 (da) Identificering af overflade-associerede antigener til tumordiagnose
HRP20192262T1 (hr) Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc)
JP2017525336A5 (me)
JP2019536426A5 (me)
CN112472802B (zh) 一种细菌外膜囊泡、包含该细菌外膜囊泡的通用纳米疫苗及其制备方法和应用
CN107522772B (zh) 短肽、其作为疫苗佐剂的应用及以所述短肽作为疫苗佐剂的疫苗
HRP20210528T1 (hr) Novi peptidi i kombinacija peptida i njihovih skela za uporabu u imunoterapiji protiv kolorektalnog karcinoma i drugih karcinoma
HRP20191671T1 (hr) Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
JP2020191873A5 (me)
HRP20211580T1 (hr) Novi peptidi i kombinacije peptida za upotrebu u imunoterpiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova